The predicated demise of racemic new molecular entities is an exaggeration
- 30 November 2012
- journal article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 11 (12), 972-973
- https://doi.org/10.1038/nrd3657-c1
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Pharmaceutical Lifecycle ManagementPublished by Wiley ,2012
- 2011 FDA drug approvalsNature Reviews Drug Discovery, 2012
- The strategy of enantiomer patents of drugsDrug Discovery Today, 2010
- Trends in the development of chiral drugsDrug Discovery Today, 2004
- Putting chirality to work: the strategy of chiral switchesNature Reviews Drug Discovery, 2002
- FDA'S policy statement for the development of new stereoisomeric drugsChirality, 1992
- Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacologyEuropean Journal of Clinical Pharmacology, 1984